CancerLivER: Biomarker Card

Biomarker Card: Comprehensive information about a biomarker


Biomarker ID 2503
Detailed information
CancerLivER ID2503
Biomarker Fibronectin, Tubulin-alpha-1 subunit, Matrix metalloproteinase 14, osteonectin SPARC, RAD23A, Ubiquitin-conjugating enzyme E2, Neutrophil-gelatinase associated lipocalin precursor lipocalin 2, TRAM protein, ADP/ATP carrier protein, High mobility group protein, Insulin stimulated protein kinase 1, Tr
Biomarker Name/Symbol (given in Publication)Fibronectin, Tubulin-alpha-1 subunit, Matrix metalloproteinase 14, osteonectin SPARC, RAD23A, Ubiquitin-conjugating enzyme E2, Neutrophil-gelatinase associated lipocalin precursor lipocalin 2, TRAM protein, ADP/ATP carrier protein, High mobility group protein, Insulin stimulated protein kinase 1, Transforming protein rhoA H12, Interferon gamma antagonist, Macrophage inhibitory cytokine 1, Betaine homocysteine S-methyltransferase, metalothionein-III, methylenetetrahydrofolate dehydrogease, metalloproteinase inhibitor1, aldehyde oxidase, uridine diphosphoglucose pyrophosphorylase, alpha-2 microglobulin, alpha-2 microglobulin receptor associated protein, TGF-beta, hepatocyte growth factor like protein, NGF-inducible anti-proliferative protein PC3, Early growth response protein 1, insulin like growth factor binding protein 3, insulin like growth factor binding protein 4, Interferon induced protein MXA, interferon-inducible protein 9-27, nuclear hormone receptor, plasminogen, haemoglobin alpha unit, decorin, c-myc oncogene, cyclin-dependent kinase inhibitor 1, DNA binding protein CPBP, transforming protein rho B, IgG, IgGK, IgG3, IgG1, IgG1K, IgA1, IgHA, IgG1-Fc, lymphocyte antigen
BiomoleculeRNAs
SubjectHuman
Degree of ValidityPotential diagnostic marker for HCC and diffrenetially expressed in HCC v/s non-tumor; but not validated on independent dataset
Experimental ConditionHCC v/s non-tumor
Cancer typeHepatocellular carcinoma
RegulationDiffrenetially expressed in HCC v/s non-tumor
Level of significance p < 0.01
SourceTissue
PMID11973655
Type of BiomarkerDiagnostic
PathwayMetabolic pathways, growth factor, regulate immune response, cell cycle, traffiking pathways
Cohort15 HCC patients: 8 HCV positive-HCC, 6 HBV-positive HCC and one HCV and HBV associated HCC. Histological analysis of non-tumour tissues showed that 11 HCCs had developed on cirrhotic and 4 on non-cirrhotic tissues; 5 well differentiated HCCs, and 10 moderately or poorly differentiated HCC.
SensitivityNA
SpecificityNA
AccuracyNA
AUCNA
DiseaseHCC v/s non-tumor
Year of Publication2002
Clinical trialNO
Clinical trial (NCT Number)NA

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top